Pain Management

Walmart Offers Unique Opioid Disposal Solution With DisposeRx

By January 17, 2018

Packets contain a crosslinking polymer blend that, when added to the pill bottle with warm water, sequester any form of prescription drugs - including powders, pills, tablets, capsules, liquids or patches - into a non-divertible and biodegradable gel.

Pharmacological Migraine Prophylaxis Guidelines

January 12, 2018

Guidelines for pharmacological prophylaxis of migraines chart

Comprehensive Examination of Impact of Tamper-Resistant Oxycodone

January 12, 2018

The researchers observed reduced sales of higher strengths of controlled-release oxycodone and increased sales of other oxycodone formulations.

Is Complete Handover of Anesthesia Care Safe?

January 10, 2018

The primary outcome (composite of all-cause death, hospital readmission, or major postoperative complications within 30 postoperative days) occurred in 44 and 29% of the complete-handover and no-handover groups, respectively, in the unweighted sample.

New Guidelines Published on Opioid Use in Refractory RLS Treatment

By January 09, 2018

Although the research found opioid use to have a favorable risk-benefit ratio, other avenues of treatment should be considered before opioid prescription including addressing iron stores and combination therapy.

Significant Migraine Risk Reduction Seen With Eptinezumab in Phase 3 Trial

By January 08, 2018

The 'PROMISE 2' study included 1,072 patients who were randomized to receive eptinezumab (300mg or 100mg), or placebo once every 12 weeks.

Trends in Gabapentinoid Use Explored in U.S. Adult Population

January 02, 2018

More than three-fold increase in percentage of adults using gabapentin and/or pregabalin

Best Practices for Improving Opioid Tapering Discussions Identified

January 02, 2018

Patients should understand individualized reasons for tapering, know their providers will not abandon them

Topical Analgesic Use Improves Pain, Opioid Discontinuation in Study

By December 27, 2017

The analysis evaluated changes in opioid use, other concurrrent medication use, and pain severity and interference in opioid-experienced patients

FDA to Review Fremanezumab for Migraine Prevention

By December 19, 2017

Results from the CM trial found that the fremanezumab arm experienced statistically significant reduction in the number of monthly headache days of at least moderate severity vs. placebo.

Monthly Galcanezumab Beneficial for Episodic Migraine Prevention

December 19, 2017

The researchers found that, compared to placebo, galcanezumab (120mg) significantly reduced migraine headache days (99.6% posterior probability, −4.8 days).

Arymo ER Tentatively Approved for Expanded Abuse Deterrence Claim

By December 15, 2017

The abuse deterrent data was not included in the original New Drug Application (NDA) label at time of approval due to exclusivity granted to another company.

Urine Drug Monitoring Recommendations for Opioid Use in Chronic Pain

By December 15, 2017

For low-risk patient, testing should be conducted at least yearly, for those at moderate risk, ≥2 times a year, and for those at high risk, ≥3 times a year.

Successful Treatment of Migraine With Antiviral/NSAID Combo

By December 14, 2017

Previous literature has speculated on an association between migraine headache and HSV.

Perioperative Gabapentin Use May Promote Post-Op Opioid Cessation

December 14, 2017

But perioperative gabapentin is linked to increase in rate of opioid cessation after surgery

Do Pre-Op Cholesterol Levels Impact Post-Op Pain Outcomes?

December 13, 2017

The researchers observed a weak, but significant, positive correlation between total cholesterol and numeric rating scale scores on post operative days 0 and 1.

Hospital Discharge Prescription Opioid Volume Varies

December 13, 2017

Overall, 35.7% of patients used no opioids in the 24 hours before discharge; 45.6% of these patients were prescribed opioids at hospital discharge.

Provider Perspectives Assessed on Medical Marijuana Use for Pediatric Cancer

December 12, 2017

Of the 288 responses, the researchers found that one-third of respondents were legally eligible to certify (ETC). Thirty percent of providers reported receiving at least 1 request for MM in the previous month.

FDA to Review Galcanezumab for Migraine Prevention in Adults

By December 11, 2017

The application includes data from three Phase 3 trials; Evolve-1, Evolve-2 (6 months) and Regain (3 months).

Novel Post-Surgical Pain Drug Granted Fast Track Designation

By December 07, 2017

An ongoing Phase 1b trial is currently testing CA-008 in patients undergoing bunionectomy, with results expected in the first quarter of 2018.

FDA to Review Novel Buprenorphine SL Spray for Acute Pain

By December 06, 2017

Compared to other commonly used opioids, buprenorphine offers a ceiling effect for respiratory depression and less abuse potential, less cognitive impairment, and less constipation.

ASHP: Revised Standards can Build Framework for Opioid Stewardship

December 06, 2017

The new and revised standards from The Joint Commission were published in July 2017 to address some of the issues associated with over-prescribing and lack of monitoring.

Certain Drug Classes Tied to Less Frequent Driving Impairment Warnings

By December 01, 2017

More than two-thirds (85%) of those on sedatives and narcotics reported being counseled by a provider on the possibility of impaired driving.

New Treatment Option for Opioid Use Disorder Gets Approval

By December 01, 2017

Sublocade should be used as part of a complete treatment program that includes counseling and psychosocial support.

Narcotic Analgesics

November 30, 2017

A comparative chart of narcotic analgesics including formulations, strengths, and dosing intervals.

Minimally Invasive Treatment Found to Relieve Low Back Pain

November 30, 2017

Reductions in VAS, ODI, Roland Morris score for patients with acute, subacute neuroradicular pain

Novel Therapy Shown to Significantly Cut Monthly Migraine Days

By November 30, 2017

Migraine days were cut by ≥50% for half of the 140mg group, by 43.3% for the 70mg group, and by 26.6% for the placebo group.

Two New Migraine Treatment Devices Available

By November 29, 2017

The Food and Drug Administration (FDA) approval was based on several studies that demonstrated 1 hour of use with Cefaly Acute could relieve or stop the migraine headache.

Naloxone Effectiveness Compared by Route of Administration

November 28, 2017

Higher-concentration intranasal naloxone (2mg/mL) seems to have efficacy similar to that of intramuscular naloxone for reversal of opioid overdose, with no difference in adverse events.

FDA Grants Priority Review to Lofexidine for Opioid Withdrawal Management

By November 21, 2017

Lofexidine, an oral tablet, is a selective alpha 2-adrenergic receptor agonist that reduces the release of norepinephrine.